AI Could Help Improve 3D Printing Accuracy

Engineering.com | February 26, 2019

AI Could Help Improve 3D Printing Accuracy
One of the biggest challenges in additive manufacturing today is the need for greater precision and reproducibility in 3D-printed parts. A team of Purdue University researchers may have found an intriguing solution: artificial intelligence.
We have developed automated machine learning technology to help improve additive manufacturing, said Arman Sabbaghi, assistant professor of statistics. Sabbaghi and his team developed a new model-building algorithm and computer application for geometric accuracy control that could potentially improve part printing.
The machine learning technology quickly corrects computer-aided design models and produces parts with improved geometric accuracy. This method helps to ensure that the produced printed parts conform more closely to the design and remain within needed tolerances.

Spotlight

As scientific development speeds up, new approaches to manufacturing aim to get medicines to patients faster.

Related News

BISTel Previews Semiconductor Industry’s First AI Knowledge Sharing Fab Models for Chip Manufacturing

BISTel | July 21, 2020

An aging workforce, tribal knowledge and an highly siloed manufacturing organization continues to hinder progress toward achieving the fab of the future and industry 4.0. says BISTel, the world leader in engineering equipment systems and AI applications for semiconductor manufacturing. CEO, W.K. Choi, says BISTel plans to address these long-standing challenges by previewing an AI based platform that creates a first of its kind collaborative knowledge sharing fab model at this year’s 50th Semicon West, a virtual tradeshow, July 20-22. BISTel will demonstrate the new DSS on the Semiconductor Digest Webcast at 2 pm, July 21 during the annual Semicon West tradeshow. Cloud, AI, Edge, Big Data and IoT technologies have improved fortunes for semiconductor manufacturers. Many of these improvements are still limited to an individual task, equipment or process. In addition, BISTel says speedier adoption of these technologies and a collaborative approach is key to realizing long-term continuous improvement in manufacturing and sustained profitability

Read More

Baxter Biopharma Solutions Announces Novavax COVID-19 Vaccine Sterile Manufacturing Agreement

businesswire | January 11, 2021

Baxter International Inc, a worldwide pioneer in clean medicine creation and conveyance, today declared that Baxter BioPharma Solutions has gone into a consent to give clean assembling administrations to NVX-CoV2373, Novavax' COVID-19 recombinant nanoparticle immunization applicant with Matrix-M™ adjuvant. Baxter BioPharma Solutions is a head contract fabricating association that works in parenteral (injectable) drugs, including antibodies. The understanding is required to propel business scale fabricating basic for the immunization's creation and appropriation in the United Kingdom and European business sectors. Novavax' COVID-19 antibody applicant is at present in stage 3 preliminaries and has not yet been approved or affirmed for use. “The quest to develop vaccines for COVID-19 has reinforced the opportunity for industry partners to work together and contribute their unique capabilities and expertise for the benefit of all,” said Marie Keeley, vice president, Baxter BioPharma Solutions. “We welcome the opportunity to work with an innovative company like Novavax and look forward to helping bring their vaccine candidate to the market.” As per Novavax, NVX-CoV2373 contains a full-length, prefusion spike protein made utilizing Novavax' recombinant nanoparticle innovation and the organization's restrictive saponin-based Matrix-M™ adjuvant. The cleaned protein is encoded by the hereditary arrangement of the SARS-CoV-2 spike (S) protein and is created in creepy crawly cells. It can neither reason COVID-19 sickness nor would it be able to reproduce, is steady at 2°C to 8°C and is made in a prepared to-utilize fluid definition that grants circulation utilizing standard immunization production network channels. “Our priority is to bring a safe, effective COVID-19 vaccine to people around the world,” said Rick Crowley, executive vice president, chief operations officer, Novavax. “Partners like Baxter BioPharma Solutions are enabling Novavax to quickly establish a commercial supply chain network to ensure access for global populations, and ultimately help bring about an end to the global COVID-19 pandemic.” Baxter's assembling administrations for NVX-CoV2373 will happen at its cutting edge office in Halle/Westfalen, Germany. The site has wide sterile assembling capacities and regions of center, offers current great assembling rehearses (cGMP) fabricating with committed creation zones and is intended to convey items with ideal proficiency and speed to advertise. Baxter's as of late extended Halle/Westfalen office has been in activity for over 60 years. About Baxter's BioPharma Solutions Business Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise, sterile manufacturing solutions, parenteral delivery systems and customized support services needed to meet the unique challenges that parenteral products face. About Baxter Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.

Read More

Artificial Intelligence Is Shaping the U.S Vs. China Manufacturing Race

Robotics Business Review | July 09, 2020

Industrial manufacturing is undoubtedly a strong economic catalyst in both the United States and China. Artificial Intelligence represents an opportunity to not only revolutionize the industrial manufacturing space, but drive economic transformation and growth as well. While both countries have integrated AI capabilities into their industrial manufacturing operations, the United States currently holds a slight edge over in China, despite a near equal number of installed bases of AI-enabled end devices in each market. Primarily, the U.S. is more incentivized to develop approaches and strategies that encourage greater adoption of AI in industrial manufacturing. In the United States, labor has become increasingly expensive, creating an imperative to lower production costs while maintaining — or even enhancing — production. This has resulted in a boost to the ecosystem of AI in industrial applications, with several types of vendors developing partnerships to bring AI into the industrial fold: cloud service providers, smart manufacturing platform vendors, and chipset vendors among them. Domestically, optimizing operational efficiency, reducing bottlenecks in production and limiting factory resource consumption are key goals centered around AI in manufacturing.

Read More

Spotlight

As scientific development speeds up, new approaches to manufacturing aim to get medicines to patients faster.